Treatment of Refractory Infantile Spasms With Fenfluramine

Learn more about:
Related Clinical Trial
The Effect of Spa and Massage on Babies on Colic Symptoms Ketogenic Diet vs ACTH for the Treatment of Children With West Syndrome Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents Tricaprilin Infantile Spasms Pilot Study Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm Sabril Patient Registry Epilepsy Phenome/Genome Project Metabolic Abnormalities in Children With Epilepsy Genetics of Severe Early Onset Epilepsies A Novel Approach to Infantile Spasms Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile Spasms Prednisolone in Infantile Spasms- High Dose Versus Usual Dose Addition of Pyridoxine to Prednisolone in Infantile Spasms Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) Open-label Extension to Protocol 1042-0500 Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH) Evaluation of Neuroinflammation in Children With Infantile Spasms Molecular Genetics in Infantile Spasms Genetic Studies in Patients and Families With Infantile Spasms Use of the Modified Atkins Diet in Infantile Spasms Treatment of Refractory Infantile Spasms With Fenfluramine A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

Brief Title

Treatment of Refractory Infantile Spasms With Fenfluramine

Official Title

A Phase II Study of Fenfluramine for Treatment of Refractory Infantile Spasms

Brief Summary

      This is a phase II clinical trial in which children with refractory infantile spasms (also
      called epileptic spasms or West syndrome) will be treated with fenfluramine, to evaluate
      efficacy, safety, and tolerability. Patients with infantile spasms that have not responded to
      treatment with vigabatrin and ACTH we will be invited to participate. Study participants will
      undergo baseline video-EEG, receive treatment with fenfluramine for 21 days, and then undergo
      repeat video-EEG to determine effectiveness. Patients with favorable response will have the
      opportunity to continue treatment for up to 6 months.

Study Phase

Phase 2

Study Type


Primary Outcome

Electroclinical response (Efficacy)

Secondary Outcome

 Computational electroencephalography response (Efficacy)


Infantile Spasm



Study Arms / Comparison Groups

 Fenfluramine treatment
Description:  Open label treatment with fenfluramine. Dosage will be titrated to 0.8 mg/kg/day, for an initial duration of 21 days. Patients with favorable response will have an option to continue treatment for up to 6 months.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

April 1, 2020

Completion Date

December 31, 2021

Primary Completion Date

December 31, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Children ages 3 to 36 months, inclusive

          -  Clinical diagnosis of infantile spasms

          -  Continued epileptic spasms despite adequate treatment with ACTH and vigabatrin.

        Exclusion Criteria:

          -  Significant preexisting cardiovascular disease

          -  Exposure to any cannabinoid product within 14 days of screening

          -  Initiation or dose-titration of any second-line treatment for infantile spasms in the
             14 days prior to screening.

          -  Implantation of a vagal nerve simulator within 14 days of screening

          -  Initiation and maintenance of the ketogenic diet within 3 months of screening




3 Months - 36 Months

Accepts Healthy Volunteers



Shaun Hussain, MD, 310-206-4037, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

University of California, Los Angeles

Study Sponsor

Shaun Hussain, MD, Principal Investigator, Univeristy of California, Los Angeles

Verification Date

February 2020